The ADDF is a venture philanthropy organization focused on accelerating the discovery and development of drugs to prevent, treat, and cure Alzheimer’s. Its diverse portfolio supports novel approaches targeting the many biological pathways involved in the disease. For remynd, “this investment by the ADDF is an important recognition of the science behind REM392 and our clinical development plan,” says CEO Floor Stam.

Remynd’s lead candidate, REM392, is an orally available small molecule designed to counter the effects of pathological tau inside neurons. Pathological tau destabilizes septin filaments, which triggers abnormal calcium influx and drives both synaptic dysfunction and neurotoxic disease pathology. REM392 acts as a septin glue and helps to restore synaptic function in diseased cells while also reducing AD-associated pathology. This mechanism was first described in Science (Princen et al., 2024), with clinical findings reported in Alzheimer's & Dementia (Nuytten et al., 2025).

Gerard Griffioen, CSO of remynd, adds: “We are moving Alzheimer's drug development beyond the usual targets and mechanisms, because we believe that is where the larger gains are for patients. Our data suggest that restoring septin function can deliver robust symptomatic benefit, with the potential to also slow down the underlying disease process. The planned Phase 1b study will put this to the test in patients and generate the next body of evidence."

Remynd will use the ADDF's investment to support a study of REM392 in a cohort of symptomatic Alzheimer's disease patients, assessing safety, tolerability and pharmacokinetics alongside readouts probing cognitive effects and disease progression. "To generate the full dataset this program needs, including a broad array of exploratory and mechanistic readouts, we are continuing to secure complementary funding," adds Stam. “I see ADDF’s support as a critical contribution to advancing REM392 and it will help bring additional partners alongside us.”

“The ADDF has a long history of supporting and investing in novel approaches that expand the Alzheimer’s pipeline beyond traditional targets,” said Aaron Burstein, PharmD, Head of Search and Evaluation at the ADDF. “Remynd’s work to restore septin function and address synaptic dysfunction is one of several promising strategies helping advance our understanding of the underlying mechanisms that contribute to Alzheimer’s and broaden the range of therapeutic approaches being developed.”